Anna Ziemiecka
Warsaw, MZ 00777, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation.
Journal: Stem cell reviews and reports
Published: December 03, 2025
Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy.
Journal: International journal of molecular sciences
Published: September 08, 2024
Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
Journal: Biomedicines
Published: July 30, 2024
Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.
Journal: Stem cell reviews and reports
Published: June 23, 2024
Enhanced Electroactive Phases of Poly(vinylidene Fluoride) Fibers for Tissue Engineering Applications.
Journal: International journal of molecular sciences
Published: April 04, 2024
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Journal: Archivum immunologiae et therapiae experimentalis
Published: September 11, 2023
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Journal: Stem cell reviews and reports
Published: August 28, 2023
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
Journal: Stem cell reviews and reports
Published: March 08, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026